Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.01 USD
+0.01 (0.90%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $1.00 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.01 USD
+0.01 (0.90%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $1.00 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Zacks News
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
by Zacks Equity Research
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
by Zacks Equity Research
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
by Zacks Equity Research
Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
by Zacks Equity Research
Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
by Zacks Equity Research
New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
by Zacks Equity Research
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Iterum Therapeutics PLC (ITRM) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Iterum Therapeutics PLC (ITRM) Loses 67.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Company News for June 2, 2020
by Zacks Equity Research
Companies in the news are: MYOV, ITRM, COTY, OPK
Iterum Down as Sulopenem Antibiotic Fails in Phase III Study
by Zacks Equity Research
Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.
Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to Decline
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -17.68% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Iterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Iterum Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Iterum Therapeutics.